Evofem Biosciences Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
29
- Stock Symbol
-
EVFM
- Investments
-
2
Evofem Biosciences General Information
Description
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Contact Information
Website
www.evofem.comCorporate Office
- 12636 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
Corporate Office
- 12636 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
Evofem Biosciences Timeline
Evofem Biosciences Stock Performance
As of 13-Nov-2026, Evofem Biosciences’s current market cap is $822K with 133M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $822K | 133M | 152K | -$0.11 |
Evofem Biosciences Financials Summary
As of 30-Jun-2026, Evofem Biosciences has a trailing 12-month revenue of $18M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 56,940 | 58,247 | 50,329 | 43,717 |
| Revenue | 18,045 | 20,183 | 19,363 | 18,218 |
| EBITDA | (14,912) | 1,004 | (8,120) | 54,746 |
| Net Income | (15,282) | 391 | (8,860) | 52,979 |
| Total Assets | 7,522 | 20,274 | 23,789 | 10,554 |
| Total Debt | 55,031 | 54,548 | 45,967 | 43,373 |
Evofem Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Evofem Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Evofem Biosciences Comparisons
Industry
Financing
Details
Evofem Biosciences Competitors (34)
One of Evofem Biosciences’s 34 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Boehringer Ingelheim | Corporation | Ingelheim Am Rhein, Germany | ||||
| Daré Bioscience | Formerly VC-backed | San Diego, CA | ||||
| Agile Therapeutics | Formerly VC-backed | Princeton, NJ | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Evofem Biosciences Patents
Evofem Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12280037-B2 | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof | Active | 22-Sep-2020 | ||
| US-20220087978-A1 | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof | Active | 22-Sep-2020 | ||
| US-20260007637-A1 | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof | Pending | 22-Sep-2020 | ||
| US-12172969-B2 | Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof | Active | 05-Sep-2018 | ||
| US-20200071279-A1 | Deuterated secnidazole for use in the treatment of bacterial vaginosis and methods and uses thereof | Inactive | 05-Sep-2018 | A61K31/4164 |
Evofem Biosciences Signals
Evofem Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Evofem Biosciences Acquisitions (2)
Evofem Biosciences’s most recent deal was a Merger/Acquisition with Lupin (U.S. Commercial Women's Health Specialty Business and SOLOSEC) for . The deal was made on 15-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Lupin (U.S. Commercial Women's Health Specialty Business and SOLOSEC) | 15-Jul-2024 | Merger/Acquisition | Other Healthcare Services | ||
| Evofem Biosciences (Pharmaceuticals) | 17-Jan-2018 | Merger/Acquisition | Pharmaceuticals |
Evofem Biosciences ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Evofem Biosciences FAQs
-
When was Evofem Biosciences founded?
Evofem Biosciences was founded in 2007.
-
Where is Evofem Biosciences headquartered?
Evofem Biosciences is headquartered in San Diego, CA.
-
What is the size of Evofem Biosciences?
Evofem Biosciences has 29 total employees.
-
What industry is Evofem Biosciences in?
Evofem Biosciences’s primary industry is Pharmaceuticals.
-
Is Evofem Biosciences a private or public company?
Evofem Biosciences is a Public company.
-
What is Evofem Biosciences’s stock symbol?
The ticker symbol for Evofem Biosciences is EVFM.
-
What is the current market cap of Evofem Biosciences?
The current market capitalization of Evofem Biosciences is $822K.
-
What is Evofem Biosciences’s current revenue?
The trailing twelve month revenue for Evofem Biosciences is $18M.
-
Who are Evofem Biosciences’s competitors?
Dicerna Pharmaceuticals, Boehringer Ingelheim, Daré Bioscience, Agile Therapeutics, and Merck & Co. are some of the 34 competitors of Evofem Biosciences.
-
What is Evofem Biosciences’s annual earnings per share (EPS)?
Evofem Biosciences’s EPS for 12 months was -$0.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process